Table 2.
Effect of lovastatin – niacin combination tablet on selected laboratory parameters
| Baseline* (n = 131) | Week 4 | Week 8 | Week 12 | Week 24* (n = 114) | Normal range | |
|---|---|---|---|---|---|---|
| Hemoglobin (gm/dl) | 11.7 ± 1.6 | – | – | – | 11.8 ± 1.4 | 14 g%–18 g% |
| White cell count (cells/cmm) | 7461 ± 1426 | – | – | – | 6998 ± 1323 | 4300–10800/mm3 |
| ESR (mm 1st hour) | 24.5 ± 12.3 | – | – | – | 17.2 ± 10.2 | 0–20 mm in 1st hr |
| SGOT (IU/l) | 29.9 ± 10.0 | 29.3 ± 9.3 | 29.5 ± 12.5 | 30.1 ± 14.4 | 24.5 ± 7.4 | 0–35 IU/L |
| SGPT (IU/l) | 31.5 ± 12.7 | 29.2 ± 9.5 | 28.1 ± 8.8 | 28.0 ± 9.5 | 23.0 ± 8.0 | 0–35 IU/L |
| Alkaline Phosphatase (IU/l) | 113.3 ± 51.9 | 107.1 ± 43.7 | 101.2 ± 38.7 | 94.5 ± 30.2 | 91.1 ± 34.6 | 60–306 IU/L |
| Creatinine (mg/dL) | 0.93 ± 0.2 | 0.96 ± 0.7 | 1.01 ± 6.5 | 1.06 ± 0.7 | 1.01 ± 0.6 | <1.5 mg/dL |
| Uric acid (mg/dL) | 4.5 ± 1.1 | 4.4 ± 0.9 | 4.5 ± 0.9 | 4.4 ± 0.8 | 4.4 ± 1.0 | 2.5–8.0 mg/dL |
| Creatine kinase (mg/dL) | 146.3 ± 70.5 | 134.7 ± 62.5 | 130.0 ± 55.5 | 125.6 ± 50.7 | 115.3 ± 40.5 | 24–190 IU/L |
| Glucose fasting (mg/dL) | 90.3 ± 14.7 | – | – | – | 81.1 ± 23.5 | <110 mg/dL |
*
Mean ± 1 standard deviation
Abbreviations: ESR, erythrocyte sedimentation rate; SGOT, serum aspartate aminotransferase; SGPT, serum alanine aminotransferase.